Go Deep
Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 8,959 | -36.7 | 20.81 | 0.66 | 45,624.66 |
| Oct 2026 | 9,098 | -36.4 | 20.61 | 0.66 | 44,726.15 |
| Oct 2026 | 9,885 | -35.2 | 19.95 | 0.66 | 43,057.06 |
| Oct 2026 | 9,647 | -35.8 | 20.29 | 0.66 | 43,676.80 |
| Oct 2026 | 9,653 | -35.2 | 20.29 | 0.66 | 43,664.04 |
| Oct 2026 | 9,958 | -35.0 | 19.84 | 0.66 | 42,597.10 |
| Oct 2026 | 10,038 | -34.8 | 19.72 | 0.66 | 42,391.46 |
| Oct 2026 | 9,419 | -36.4 | 20.63 | 0.66 | 44,330.45 |
| Oct 2026 | 9,709 | -35.6 | 20.20 | 0.66 | 43,314.85 |
| Oct 2026 | 9,849 | -35.3 | 20.00 | 0.66 | 42,791.14 |
Madrigal Pharmaceuticals, Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 364,252,000.0 | 311,337,000.0 | 321,083,000.0 | 287,268,000.0 |
| Net Profit | -57,939,000.0 | -94,391,000.0 | -58,575,000.0 | -114,190,000.0 |
| EPS | -2.0 | -3.2 | -2.6 | -5.1 |
Madrigal Pharmaceuticals, Inc. Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 958,403,000.0 | 180,133,000.0 | 0.0 | 0.0 | — |
| Net Profit | -288,284,000.0 | -465,892,000.0 | -373,630,000.0 | -295,350,000.0 | — |
| EPS | -12.8 | -21.9 | -20.0 | -17.2 | — |
Madrigal Pharmaceuticals, Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 1,259,589,000.0 | 1,042,247,000.0 | 640,547,000.0 | 362,572,000.0 | — |
| Total Liabilities | 656,900,000.0 | 287,864,000.0 | 235,214,000.0 | 165,183,000.0 | — |
| Total Equity | 602,689,000.0 | 754,383,000.0 | 405,333,000.0 | 197,389,000.0 | — |
Owes vs Owns
Madrigal Pharmaceuticals, Inc. owed $0.58 for every $1 it owned in Jun 2026, up from $0.46 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.58× | 0.52× | 0.28× | 0.37× | 0.46× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Madrigal Pharmaceuticals, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 78.1%Receivables 10.7%Inventory 5.9%Fixed assets (tangible) 0.5%Intangible assets 0.6%Other assets 4.2%
How it's funded — Dec 2025
Long-term debt 27.0%Payables 3.9%Other liabilities 21.2%Shareholders' equity 47.8%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 983.6 | 926.3 | 634.1 | 358.8 |
| Receivables | 134.5 | 53.8 | 0.0 | 0.0 |
| Inventory | 74.8 | 34.1 | 0.0 | 0.0 |
| Fixed assets (tangible) | 6.4 | 4.6 | 3.3 | 1.2 |
| Intangible assets | 7.4 | 4.7 | 0.0 | 0.0 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 52.9 | 18.8 | 3.1 | 2.6 |
| Liabilities & equity | ||||
| Short-term debt | 1.0 | 1.0 | 0.5 | 0.6 |
| Long-term debt | 339.9 | 117.6 | 115.5 | 49.3 |
| Payables | 48.9 | 43.6 | 28.0 | 23.8 |
| Other liabilities | 267.1 | 125.7 | 91.2 | 91.5 |
| Shareholders' equity | 602.7 | 754.4 | 405.3 | 197.4 |
| Net tangible assets | 595.3 | 749.7 | 405.3 | 197.4 |
Madrigal Pharmaceuticals, Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Operating Activities | -189,553,000.0 | -455,572,000.0 | -324,230,000.0 | -224,857,000.0 |
| Investing Activities | 32,320,000.0 | -274,386,000.0 | -502,520,000.0 | 206,686,000.0 |
| Financing Activities | 255,984,000.0 | 735,062,000.0 | 595,116,000.0 | 313,451,000.0 |